Actuate Therapeutics Statistics
Total Valuation
ACTU has a market cap or net worth of $129.29 million. The enterprise value is $125.40 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ACTU has 19.62 million shares outstanding. The number of shares has increased by 766.91% in one year.
Current Share Class | 19.62M |
Shares Outstanding | 19.62M |
Shares Change (YoY) | +766.91% |
Shares Change (QoQ) | -0.26% |
Owned by Insiders (%) | 4.88% |
Owned by Institutions (%) | 2.60% |
Float | 5.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.46
Current Ratio | 0.46 |
Quick Ratio | 0.42 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,269.95 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -413.43% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 508.53% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.53M |
Employee Count | 10 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
ACTU does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -766.91% |
Shareholder Yield | -766.91% |
Earnings Yield | -19.57% |
FCF Yield | n/a |
Analyst Forecast
The average price target for ACTU is $20.00, which is 203.49% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $20.00 |
Price Target Difference | 203.49% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |